WO2010103469A1 - Sonolyse de caillots sanguins utilisant des impulsions d'excitation codées de faible puissance - Google Patents

Sonolyse de caillots sanguins utilisant des impulsions d'excitation codées de faible puissance Download PDF

Info

Publication number
WO2010103469A1
WO2010103469A1 PCT/IB2010/051031 IB2010051031W WO2010103469A1 WO 2010103469 A1 WO2010103469 A1 WO 2010103469A1 IB 2010051031 W IB2010051031 W IB 2010051031W WO 2010103469 A1 WO2010103469 A1 WO 2010103469A1
Authority
WO
WIPO (PCT)
Prior art keywords
microbubbles
sonolysis
transmit
waveform
energy
Prior art date
Application number
PCT/IB2010/051031
Other languages
English (en)
Inventor
Jeffry E. Powers
Vijay Shamdasani
Original Assignee
Koninklijke Philips Electronics, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics, N.V. filed Critical Koninklijke Philips Electronics, N.V.
Publication of WO2010103469A1 publication Critical patent/WO2010103469A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • A61B8/467—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient characterised by special input means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/225—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves
    • A61B17/2256—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for for extracorporeal shock wave lithotripsy [ESWL], e.g. by using ultrasonic waves with means for locating or checking the concrement, e.g. X-ray apparatus, imaging means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/46—Ultrasonic, sonic or infrasonic diagnostic devices with special arrangements for interfacing with the operator or the patient
    • A61B8/461—Displaying means of special interest
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/48—Diagnostic techniques
    • A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • A61B2017/22005—Effects, e.g. on tissue
    • A61B2017/22007—Cavitation or pseudocavitation, i.e. creation of gas bubbles generating a secondary shock wave when collapsing
    • A61B2017/22008—Cavitation or pseudocavitation, i.e. creation of gas bubbles generating a secondary shock wave when collapsing used or promoted
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
    • A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
    • A61B2017/22014—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being outside patient's body; with an ultrasound transmission member; with a wave guide; with a vibrated guide wire
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
    • A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
    • A61B2017/22089—Gas-bubbles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
    • A61B34/25—User interfaces for surgical systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
    • A61B8/0808—Detecting organic movements or changes, e.g. tumours, cysts, swellings for diagnosis of the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/13—Tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0039—Ultrasound therapy using microbubbles

Definitions

  • This invention relates to medical diagnostic ultrasound systems and, in particular, to ultrasound systems which can be optimized to dissolve blood clots and similar occlusions.
  • the blood clot lysis system shown in the Browning et al . application can be operated at acoustic output levels which are approved for diagnostic imaging.
  • MI mechanical index
  • Such high power transmission is conventionally used in "flash" contrast imaging, when the high transmit energy breaks or collapses the microbubbles in the path of the ultrasound and this breakage is observed as a "flash” of the image and/or used as a prelude to evaluating the return (re-perfusion) of microbubbles into the region where the microbubbles were depleted by the flash transmission.
  • flash contrast imaging when the high transmit energy breaks or collapses the microbubbles in the path of the ultrasound and this breakage is observed as a "flash” of the image and/or used as a prelude to evaluating the return (re-perfusion) of microbubbles into the region where the microbubbles were depleted by the flash transmission.
  • the present inventors have determined that more effective blood clot lysis can be achieved, not by strongly disrupting or breaking the microbubbles adjacent to the blood clot, but by agitating these adjacent microbubbles gently without breaking them, and thus prolong the agitation effect.
  • CHIRP frequency modulated
  • monitor microbubble agitation for blood clot lysis so that the desirable effect may be controlled and prolonged during therapy.
  • a diagnostic ultrasound system and method which promote ultrasonic blood clot lysis by gently agitating microbubbles adjacent to a blood clot in a blood vessel.
  • Low transmit energy is used so that the microbubbles are gently jiggled or oscillated or vibrated with reduced microbubble destruction.
  • the voltage of the transmitted ultrasound pulses is ten volts or less and/or the in situ MI of the transmit pulses is at or below an MI of 0.1.
  • the pulses transmitted for microbubble oscillation are preferably coded pulses such as frequency modulated (CHIRP) pulses.
  • the coded pulses can be transmitted as discrete pulses or as a continuous wave (CW) modulated signal.
  • FIGURE 1 illustrates in block diagram form an ultrasonic diagnostic imaging system constructed in accordance with the principles of the present invention .
  • FIGURE 2 illustrates three dimensional ultrasonic transcranial diagnosis in accordance with the present invention.
  • FIGURE 3 illustrates two dimensional ultrasonic transcranial diagnosis in accordance with the present invention .
  • FIGURE 4 illustrates the transmission of low energy CHIRP pulses to produce sonolysis of a transcranial blood clot.
  • FIGURES 5a-5d illustrate various CHIRP pulses which may be used in a constructed embodiment of the present invention.
  • FIGURE 6 illustrates a method for manual control of sonolysis in accordance with the present invention .
  • FIGURE 7 illustrates a first automatic method for feedback control of sonolysis.
  • FIGURE 8 illustrates in block diagram form the monitoring portion of a sonolysis ultrasound system constructed in accordance with the principles of the present invention.
  • FIGURES 9a-9c illustrate received ultrasound signals and passbands which may be employed in an implementation of the system of FIGURE 8.
  • FIGURE 10 illustrates a second automatic method for feedback control of sonolysis.
  • FIGURE 11 is an example of a display produced by an ultrasound system or method in accordance with the principles of the present invention.
  • FIGURE 1 an ultrasound system constructed in accordance with the principles of the present invention is shown in block diagram form.
  • the example of FIGURE 1 is a system for diagnosing and treating cranial blood clots which may cause stroke.
  • the present invention may be employed to treat occlusions in other parts of the body such as myocardial, peripheral vascular, and renal occlusions.
  • two transducer arrays 10a and 10b are provided for transmitting ultrasonic waves and receiving echo information.
  • the arrays shown are two dimensional arrays of transducer elements capable of scanning in three dimensions for 3D imaging and treatment, although an implementation of the present invention may also use one dimensional arrays of transducer element which produce 2D (planar) images and treatment beams.
  • the transducer arrays are coupled to microbeamformers 12a and 12b which control the transmission and reception of ultrasound signals by the array elements.
  • Microbeamformers are also capable of at least partial beamforming of the signals received by groups or "patches" of transducer elements as described in US Pats. 5,997,479 (Savord et al . ) , 6,013,032 (Savord), and 6,623,432 (Powers et al . )
  • Signals are routed to and from the microbeamformers by a multiplexer 14 by time-interleaving signals.
  • the multiplexer is coupled to a transmit/receive (T/R) switch 16 which switches between transmission and reception and protects the main beamformer 20 from high energy transmit signals.
  • T/R transmit/receive
  • the transmission of ultrasonic beams from the transducer arrays 10a and 10b under control of the microbeamformers 12a and 12b is directed by the transmit controller 18 coupled to the T/R switch, which receives input from the user's operation of the user interface or control panel 38.
  • the transmit controller 18 coupled to the T/R switch, which receives input from the user's operation of the user interface or control panel 38.
  • the user can control transmit parameters such as transmit voltage, MI, frequency modulation, pulse length, PRF (pulse repetition frequency), and the like.
  • the partially beamformed signals produced by the microbeamformers 12a, 12b are coupled to a main beamformer 20 where partially beamformed signals from the individual patches of elements are combined into a fully beamformed signal.
  • the main beamformer 20 may have 128 channels, each of which receives a partially beamformed signal from a patch of 12 transducer elements. In this way the signals received by over 1500 transducer elements of a two dimensional array transducer can contribute efficiently to a single beamformed signal.
  • the beamformed signals are coupled to a fundamental/harmonic signal separator 22.
  • the separator 22 acts to separate linear and nonlinear signals so as to enable the identification of the strongly nonlinear echo signals returned from microbubbles .
  • the separator 22 may operate in a variety of ways such as by bandpass filtering the received signals in fundamental frequency and harmonic frequency bands, or by a process known as pulse inversion harmonic separation.
  • a suitable fundamental/harmonic signal separator is shown and described in international patent publication WO
  • the separated signals are coupled to a signal processor 24 where they may undergo additional enhancement such as speckle removal, signal compounding, and noise elimination.
  • the processed signals are coupled to a B mode processor 26 and a Doppler processor 28.
  • the B mode processor 26 employs amplitude detection for the imaging of structures in the body such as muscle, tissue, and blood cells. B mode images of structure of the body may be formed in either the harmonic mode or the fundamental mode or a combination of both as described in US Pat. 6,283,919 (Roundhill et al.) and US Pat. 6,458,083 (Jago et al .
  • Tissues in the body and microbubbles both return both types of signals and the stronger harmonic returns of microbubbles enable microbubbles to be clearly segmented in an image in most applications.
  • the Doppler processor processes temporally distinct signals from tissue and blood flow for the detection of motion of substances in the image field including microbubbles.
  • the structural and motion signals produced by these processors are coupled to a scan converter 32 and a volume renderer 34, which produce image data of tissue structure, flow, or a combined image of both characteristics.
  • the scan converter will convert echo signals with polar coordinates into image signals of the desired image format such as a sector image in Cartesian coordinates.
  • the volume renderer 34 will convert a 3D data set into a projected 3D image as viewed from a given reference point as described in US Pat. 6,530,885 (Entrekin et al . ) As described therein, when the reference point of the rendering is changed the 3D image can appear to rotate in what is known as a kinetic parallax display. This image manipulation is controlled by the user as indicated by the Display Control line between the user interface 38 and the volume renderer 34. Also described is the representation of a 3D volume by planar images of different image planes, a technique known as multiplanar reformatting.
  • the volume renderer 34 can operate on image data in either rectilinear or polar coordinates as described in US Pat. 6,723,050 (Dow et al . )
  • the 2D or 3D images are coupled from the scan converter and volume renderer to an image processor 30 for further enhancement, buffering and temporary storage for display on an image display 40.
  • a graphics processor 36 is also coupled to the image processor 30 which generates graphic overlays for displaying with the ultrasound images. These graphic overlays can contain standard identifying information such as patient name, date and time of the image, imaging parameters, and the like, and can also produce a graphic overlay of a spatial indication of cavitation as described below. For these purposes the graphics processor receives input from the user interface 38.
  • the user interface is also coupled to the transmit controller 18 to control the generation of ultrasound signals from the transducer arrays 10a and 10b and hence the images produced by and therapy applied by the transducer arrays.
  • the transmit parameters controlled in response to user adjustment include those mentioned above, as well as the steering of the transmitted beams for image positioning and/or positioning
  • the transmit voltage or MI is controlled during therapy to prolong the gentle jiggling or vibration of the microbubbles without causing their destruction, which would result in a cessation of the desired therapeutic effect.
  • the transducer arrays 10a and 10b transmit ultrasonic waves into the cranium of a patient from opposite sides of the head, although other locations may also or alternately be employed such as the front of the head or the sub-occipital acoustic window at the back of the skull.
  • the sides of the head of most patients advantageously provide suitable acoustic windows for transcranial ultrasound through the skull at the temporal bones around and above the ears on either side of the head.
  • the transducer arrays In order to transmit and receive echoes through these acoustic windows the transducer arrays must be in good acoustic contact at these locations, which may be done by holding the transducer arrays against the head with a headset .
  • low attenuation effects may enable an image field to extend fully across the cranium, allowing the clinician to examine the vascular structure near the skull bone on the opposite side of the cranium.
  • image fields of both transducer arrays By alternately examining image fields of both transducer arrays, the vasculature across the full cranium may be effectively examined. It is possible to acquire extended image fields which cover the same central region of the cranium but image from opposite sides of the head. These images can be correlated and compounded together, forming a fused image that may reveal additional characteristics of the brain.
  • a therapeutic beam 110 or 112 is transmitted and steered at the clot to break it up (sonolysis) either with the ultrasonic energy alone, but preferably in combination with microbubbles introduced into the bloodstream.
  • the infusion of microbubbles may also be accompanied by application of a thrombolytic drug such as tissue plasminogen activator (tPA) .
  • tPA tissue plasminogen activator
  • the therapeutic beam 110,112 can also be transmitted from both sides of the head, enabling breakup of a clot from both sides of the clot.
  • through-transmission imaging can be performed by transmitting ultrasound from one transducer array and receiving the remaining unabsorbed ultrasonic energy at the other transducer array, which may reveal yet other characteristics of the brain tissue.
  • FIGURE 3 illustrates a two dimensional imaging example of the present invention.
  • the transducer array 122 is a one dimensional array or portion of a 2D array which performs 2D imaging.
  • the array may be configured as a circular phased array transducer as described in US Pat. 5,226,422.
  • This transducer array like the other arrays described herein, is covered with a lens 124 which electrically insulates the patient from the transducer array and in the case of a one dimensional array may also provide focusing in the elevation (orthogonal to the plane) dimension.
  • the transducer array 122 is backed with acoustic damping material 126 which attenuates acoustic waves emanating from the back of the array to prevent their reflection back into the transducer elements.
  • Behind this transducer stack is a device 130 for rotating the image plane 140 of the array.
  • the device 130 may be a simple knob or tab which may be grasped by the clinician to manually rotate the circular array transducer in its rotatable transducer mount (not shown) .
  • the device 130 may also be a motor which is energized through a conductor 132 to mechanically rotate the transducer as discussed in US Pat. 5,181,514 (Solomon et al .
  • Rotating the one dimensional array transducer 122 as indicated by arrow 144 will cause its image plane 140 to pivot around its central axis, enabling the repositioning of the image plane for full examination of the vasculature in front of and in the imaging plane of the transducer array.
  • the planes acquired during at least a 180° rotation of the array will occupy a conical volume in front of the transducer array, which may be rendered into a 3D image of that volumetric region.
  • Other planes outside this volumetric region may be imaged by repositioning, rocking or tilting the transducer array in its headset in relation to the skull 100.
  • the therapeutic beam vector graphic 142 can be steered by the clinician to aim the therapeutic beam at the stenosis and therapeutic pulses applied to disrupt the microbubbles at the site of the stenosis.
  • low energy transmission is used during sonolysis to prolong the therapeutic effect by vibrating or oscillating or jiggling the microbubbles without causing extensive destruction of the microbubbles.
  • a standard cart-mounted ultrasound system with conventional piezoelectric ceramic transducers may drive the transducer elements with voltages up to 200 volts and still be within the regulatory limits of diagnostic ultrasound.
  • the transducer elements are driven with much lower transmit voltages, preferably less than ten volts. Typical low voltage ranges may be 3-4 volts or 5-6 volts, for instance.
  • Another parameter which may be controlled to maintain low energy transmission is the mechanical index (MI) of the transmit waveforms.
  • the mechanical index is a measure of the peak negative pressure of a transmit waveform divided by the square root of the frequency of the waveform.
  • the MI provides an indicator which is a measure of the cavitational effects of the transmitted ultrasound.
  • MI 1.9.
  • MI of the pulse waveform in situ that is, at the microbubbles where the ultrasound energy is being delivered.
  • the transmitted waveform will experience a substantial amount of attenuation as it travels through the skull.
  • the low energy therapeutic transmit pulses are transmitted as long pulses which jiggle or vibrate the microbubbles with a relatively long interval of low energy.
  • the transmit pulses are generally very short, only a cycle or two. This provides a broad signal bandwidth but is also mandated by the other regulatory limit, the thermal limit. Only a few cycles of a transmit pulse at high MI are required before unacceptable heating of the probe occurs and the SPTA limit is exceeded.
  • a low energy pulse such as three to ten volts or an MI of 0.1 to 0.2, the transmit level is too low to cause rapid heating and hence the transmit waveform can be extended over many cycles.
  • a sonolysis therapeutic pulse of the present invention may be dozens or hundreds of cycles long.
  • the transmit pulse frequency is in the range of 500 kiloHertz to 2 MHz.
  • the pulse length can range from 5-10 microseconds to very long pulses for near continuous operation.
  • the transmitted therapeutic pulse is frequency modulated.
  • a preferred frequency modulated pulse is a CHIRP pulse, which starts at a low frequency and is modulated up to a higher frequency during successive cycles of the transmit waveform, or vice versa.
  • a frequency modulated pulse There are two advantages of the use of a frequency modulated pulse. One is that microbubbles of different sizes are resonant at different frequencies and thus are more responsive to select transmit frequencies. Transmitting a frequency modulated pulse causes microbubbles of a greater variation in sizes to be energized into vibration or oscillation. The second advantage of a frequency modulated pulse such as a CHIRP pulse is greater resolution when imaging is performed during the therapy.
  • CHIRP waveform The correlation of a CHIRP waveform and its resulting echo signal closely approximates an impulse response, which provides a sharp delineation of the round-trip travel time of the pulse and thus good axial resolution during ultrasound imaging.
  • This correlation can be performed by a matched filter and, as discussed below, by the quadrature bandpass filter (QBP) which can be used for ultrasound signal demodulation as described in US Pat. 6,050,942 (Rust et al . )
  • QBP quadrature bandpass filter
  • a CHIRP pulse 312 is directed toward the microbubbles 204 which are adjacent to a blood clot 202 in a cranial blood vessel 200.
  • the low energy delivered by the long CHIRP pulse 312 causes the microbubbles 204 to gently vibrate without substantial breakage, thereby delivering a prolonged therapeutic effect to break up the blood clot 2002.
  • FIGURE 5 illustrates several modulation techniques which can be used to produce a therapeutic CHIRP pulse for sonolysis.
  • FIGURE 5a illustrates a linear CHIRP pulse 312 in which the frequency of the waveform is incremented linearly from a low frequency to a high frequency as indicated by line 314 in FIGURE 5b.
  • Another way to modulate the CHIRP pulse is quadratically as shown by the quadratic CHIRP pulse 322 in FIGURE 5c.
  • This CHIRP pulse is produced by modulating the waveform frequency non-linearly as shown by the curve 324 in FIGURE 5d.
  • the frequency modulation of the CHIRP therapeutic pulse can be from a low frequency to a high frequency or from a high frequency to a low frequency.
  • CHIRP pulses can be repeated, with one CHIRP pulse being produced immediately following another, thereby creating an even longer CHIRP pulse.
  • the frequency modulation can be the same for each successive CHIRP pulse, or can be alternated or varied from pulse to pulse in the long multiple-pulse sequence.
  • CHIRP waveforms can be transmitted one after the other for (nearly) continuous therapeutic operation.
  • FIGURE 6 illustrates a method for delivering sonolysis therapy in accordance with the present invention.
  • a transducer 122, 10a, or 10b is coupled to the body of the patient and the region of the body which may contain a blood clot is imaged to locate a clot 202, such as by detection of a blockage of blood flow in a vessel 200 with Doppler ultrasound.
  • Microbubbles 204 are infused into the patient's blood stream at step 602 and flow to the site of the obstruction.
  • the ultrasound energy is then increased in step 604 until it is observed or detected that the microbubbles are being disrupted.
  • the user dials back the energy control of the ultrasound system to a low energy level at step 606, which stabilizes the microbubbles in a state in which they are being gently agitated at the site of the blockage.
  • the blood clot should be broken up in a few minutes by ultrasonic blood clot lysis.
  • FIGURE 7 illustrates an automated method for performing blood clot lysis in accordance with the present invention.
  • the blood clot 202 is detected in the ultrasound imaging field 102, 104, or 140 and microbubbles 204 are infused into the blood stream of the patient and flow to the site of the blockage in step 702.
  • the microbubbles are insonified with ultrasound energy and the ultraharmonic and/or subharmonic content of the echo signals is measured at step 708.
  • An indication of ultraharmonic or subharmonic content is indicative of stable cavitation, whereas a return of broadband noise is indicative of inertial cavitation, in which the microbubbles are being excessively agitated and severely disrupted.
  • the energy level of the therapeutic ultrasound is reduced to a lower level at step 710 to stabilize the microbubbles in a state of stable cavitation.
  • feedback of the measurement of the ultraharmonic or subharmonic content is used to maintain a steady jiggling or oscillation of the microbubbles 204 for blood clot lysis.
  • An ultrasound probe 60 has a transducer array 10 coupled by T/R switch 16 to a transmit beamformer 20a which controls the transmission of therapeutic beams by the transducer array 10 and to a receive beamformer 20b which beamforms echo signals received from the transducer array elements 10.
  • the beamformed echo signals are processed by a quadrature bandpass (QBP) filter 62.
  • QBP filters are commonly used in ultrasound systems to filter received echo signals, produce I and Q quadrature signal components for Doppler and coherent image processing and provide sampling decimation.
  • the QBP filter can also perform correlation of transmitted and received CHIRP waveforms to detect CHIRP echoes and image the microbubbles and surrounding tissue.
  • QBP filters are generally described in US Pat. 6,050,942 (Rust et al . ) , for example.
  • the QBP filter also filters the echo signals into two passbands, an SC band and an IC band such as those shown in FIGURE 9.
  • the signal content of the SC and IC bands is then analyzed by a cavitation comparator 70 which may analyze the SC signal content alone for its energy content or in comparison with a threshold level, or may analyze the SC signal content in comparison with the IC signal content. The result of the analysis will indicate the presence of stable cavitation, inertial cavitation, or both or neither.
  • the result of the cavitation analysis is used in an automated implementation to control the transmit energy level of the transducer array 10. This is done in this example by coupling a cavitation control signal from the cavitation comparator 70 to the power control input of the transmit beamformer 20a.
  • the cavitation control signal will vary the transmit power until a maximum response is detected in the SC passband, at which point that transmit power level is maintained to maintain stable cavitation.
  • the response of the SC passband can be compared with that of the IC passband and the transmit power level controlled to obtain the desired SC to IC band ratio.
  • the user will control the transmit power from the transmit power control of the user interface 38 as shown in step 606 of FIGURE 6.
  • stable cavitation will begin to occur, producing subharmonic energy in the SC passband which is detected by the cavitation comparator, either alone or in combination with higher frequency energy of the IC passband.
  • a control signal is coupled to a user alert 72 which issues an audible or visual alert to the user.
  • the audible alert can comprise a tone of a given frequency or amplitude from a speaker 42 when stable cavitation is detected, and can change to or be mixed with a tone of a different frequency or sound when inertial cavitation is detected. The user will then adjust the power level until the stable cavitation tone is continuously heard without interruption by the inertial cavitation tone.
  • a visual indication 44 can be presented, such as a green light when stable cavitation is detected and changing to a red light when inertial cavitation is present. The user will adjust the power for a solid green light in that example .
  • FIGURES 9a-9c illustrate the signal processing of the subharmonic and ultraharmonic echo content.
  • FIGURE 9a illustrates a range of frequencies for a transmit pulse or wave and its echo components.
  • the therapeutic transmit pulse f tr is a long CHIRP pulse (long sample volume) directed at a blood clot.
  • a transmit pulse f tr is reflected by a microbubble the reflected echo will have significant harmonic content due to the nonlinear behavior of the microbubble in the acoustic field.
  • the second harmonic component 2f tr and the third harmonic, 3f tr? are also illustrated in FIGURE 9a.
  • the transmitted wave will also be distorted by its passage through tissue which will also generate nonlinear echo returns, but generally at lower levels than the harmonic echo returns from microbubbles .
  • the tissue harmonic components are most prevalent at the integer harmonic frequencies 2f tr and 3f tr , with successively higher harmonics being of decreasing amplitude .
  • microbubbles will exhibit different behavior.
  • the microbubbles in the body will exhibit radial expansion and contraction in response to the transmitted acoustic pressure waves.
  • this oscillation is stable and can continue for a considerable amount of time.
  • This continual agitation by the oscillating bubbles may be a phenomenon that contributes to the effectiveness of the microbubbles in breaking up a clot. Stable cavitation is maintained by maintaining the energy of the acoustic pressure waves at an intensity which produces this effect.
  • the microbubbles become unstable and break into smaller bubbles and dissolve into the surrounding blood, and at even higher acoustic pressures even within diagnostic power limits the bubbles can rupture violently and disappear. This removal of the bubbles may be a factor contributing to the relative ineffectiveness of these inertial cavitation pressure levels in promoting clot dissolution.
  • Microbubbles which are in stable cavitation will return echo signals with significant subharmonic content below the fundamental transmit frequency f tr •
  • echoes from stable cavitation can be expected to return echo signals with frequencies at a frequency of 0.5f tr as indicated in FIGURE 9a.
  • the frequency content of echoes can be analyzed to determine whether there is significant frequency content about this subharmonic frequency.
  • a bandpass filter of the QBP with a center frequency of 0.5f tr will perform this function as indicated in FIGURE 9b, in which a passband centered at this frequency will pass signal energy about this frequency.
  • the energy content of this SC passband can be examined for significant subharmonic energy content and used as an indication of stable cavitation.
  • the transmit power of the acoustic energy is then adjusted or maintained to maximize the energy content of the SC passband, thereby establishing and maintaining stable cavitation.
  • the analysis of the SC passband can be performed with respect to a predetermined threshold or by adjusting the transmit energy until a maximum response in the SC passband is produced.
  • the SC passband energy can also be compared with the energy of a frequency spectrum characteristic of inertial cavitation.
  • a passband can be established at these higher frequencies such as the IC passband illustrated in FIGURE 9b at 1.5f tr -
  • This ultraharmonic frequency is used to reduce contributions from tissue harmonic echo returns, which exhibit significant frequency content at integer harmonic frequencies such as the second harmonic 2f tr -
  • One technique of using both frequencies is to adjust the transmit power until a maximum ratio of the SC band energy to the IC energy is obtained.
  • Another approach is to increase transmit power to a level just below the occurrence of significant or detectable energy in the IC band.
  • the present invention solves this problem by detecting and identifying the type of cavitation, then allowing the user to automatically or manually control the cavitation mode.
  • the first sub-band 204a of the IC band has a lower cutoff above the fundamental frequency f tr and below 1.5f tr -
  • the passband is notched out at the second harmonic 2f tr and continues with a second sub-band 204b above the second harmonic frequency and below the third harmonic frequency 3f tr - Additional sub-bands such as 204c can also be used.
  • This IC passband captures the ultraharmonic energy of inertial cavitation events with reduced response to tissue harmonic energy at the integer harmonic frequencies.
  • a further approach is to use a narrower passband in the subharmonic range and a broader passband in the ultraharmonic range.
  • a narrow passband such as the SC passband of FIGURE 9b can be used for stable cavitation detection
  • a broader passband such as passband 204a of FIGURE 9c can be used for inertial cavitation detection.
  • FIGURE 10 illustrates a Doppler-like technique in which the microbubbles are maintained in a gently agitated state without excessive disruption. Similar to Doppler processing, this technique analyzes ensembles of temporally discrete echo signals returned from specific locations in the image field. The ensembles may be acquired over a range of PRFs such as 5kHz to 1OkHz. As before, a blood clot is imaged with the ultrasound probe 60 and microbubbles 204 are infused into the patient's blood stream in step 1002. Echo ensembles are then acquired around the location of the blood clot. The echoes of an ensemble from a given location are compared pulse-to- pulse in step 1004 (e.g., consecutive echoes) and subtracted to eliminate echo returns from stationary materials.
  • pulse-to- pulse in step 1004 (e.g., consecutive echoes) and subtracted to eliminate echo returns from stationary materials.
  • the resulting difference values thus represent the effects of motion at the ensemble location.
  • Successive difference values are then compared in step 1006 to ascertain their consistency from measurement to measurement.
  • the microbubbles are being gently vibrated or oscillated to cause the desired sonolysis, there will be microbubble motion which will manifest itself as nonzero values resulting from the step 1004 comparison.
  • the measurements from pulse-to-pulse in step 1006 will be relatively constant and stable. But if excessive energy is being applied and the microbubbles are being strongly disrupted or bursting, the difference values will vary as microbubbles are broken up into smaller microbubbles or are dissolved or disappear entirely.
  • An uneven series of measured difference values is thus an indication of excessive ultrasound energy and the transmitted therapeutic energy is adjusted to stabilize the microbubbles in their desired gently agitated state in 1008.
  • the operating state can be alerted to the user for manual user intervention or can be automatically adjusted and maintained by the ultrasound system.
  • FIGURE 11 illustrates the ultrasound system display screen 300 of an ultrasound system constructed in accordance with the present invention.
  • the display 300 in this example is displaying an ultrasound image 302 which includes tissue and vasculature.
  • the vasculature includes a major blood vessel 80, off of which is branching a smaller vessel 82 which branches into smaller capillaries 84 and 86.
  • the blood vessels will appear black in grayscale due to the low level echo returns from the blood, but can be shown in color in Doppler mode with the color indicating the motion of the blood.
  • the B mode signals from the vessels will change from black (low level) to bright (high level) when the blood flow begins to contain appreciable amounts of microbubbles.
  • the arrival of microbubbles in the blood flow can be detected adaptively from this change or the system can be baselined manually by placing a sample volume over a vessel without microbubbles and measuring the signal content, then placing the sample volume over a vessel when microbubbles are present to measure the signal content from the microbubbles.
  • Either the adaptive or manual technique can be used, in conjunction with the flow (Doppler) information if desired, to detect signals coming from microbubbles.
  • the "bubble detect" signal triggers the graphics processor 36 in FIGURE 8 to place a color in a color overlay of the image 302 which indicates the type of cavitation at each bubble location.
  • the color is determined by a cavitation signal coupled to the graphics processor from the cavitation comparator 70. For instance, if the SC signal or SC/IC ratio indicates the presence of stable cavitation at a location where a bubble is detected, a green color is added to the overlay at that bubble location, as indicated by the single hatching 90 in FIGURE 11. But when inertial cavitation is detected by the cavitation comparator, a different color is added to the overlay such as a red color at that bubble location. The red color is indicated by cross- hatching 92 in FIGURE 11. When no cavitation is detected as will occur in signals returned from tissue or blood without microbubbles, no overlay color is added and the ultrasound image will appear conventional at those locations. The cavitation color overlay is combined with the ultrasound image by the ultrasound image processor 30.
  • FIGURE 11 it is seen that stable cavitation (single hatching 90) is occurring in the lateral extremes of the major vessel 80 and into the smaller vessel 82, but that inertial cavitation (cross-hatching 92) is occurring in the center of the major vessel 80.
  • a user trying to maintain stable cavitation will then turn down the transmit power until the red color 92 is replaced with the green color 90, indicating the presence of only stable cavitation in the vasculature.
  • FIGURE 11 also shows a display indicator 304 which displays the type of cavitation detected.
  • the pointer 306 of the display indicator can point at zero, SC, or IC or between these indications.
  • the instantaneous setting of the pointer 306 is determined by a signal from the cavitation comparator to indicate the predominant type of cavitation detected. If no cavitation is detected in the image the pointer will point to zero. As stable cavitation begins to manifest itself the pointer will move to the SC indication, and if the power is turned too high and inertial cavitation begins, the pointer will move to the IC indication.
  • the pointer can indicate an average or overall cavitation content of the vasculature by summing or integrating the cavitation signals over the points in the image where microbubbles have been detected.
  • the user can place a sample volume at the site of the blood clot and the indicator 304 will report on the type of cavitation at the therapy site. The user adjusts the transmit power level to keep the pointer 306 pointing continually at the SC indication.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgical Instruments (AREA)

Abstract

La présente invention concerne un système d'imagerie diagnostique ultrasonore qui est utilisé pour réaliser la sonolyse des caillots sanguins à l'aide d'un agent de contraste à microbulles. L'énergie thérapeutique qui produit la sonolyse est un faible niveau d'énergie qui agite ou fait osciller doucement les microbulles sans les faire éclater, prolongeant ainsi l'effet de sonolyse. Le faible niveau d'énergie peut être un niveau de tension de transmission n'excédant pas dix volts, ou un MI (mechanical index) de transmission ne dépassant pas 0,2. De préférence, la forme d'onde transmise est une forme d'onde CHIRP longue à modulation de fréquence.
PCT/IB2010/051031 2009-03-12 2010-03-10 Sonolyse de caillots sanguins utilisant des impulsions d'excitation codées de faible puissance WO2010103469A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15953409P 2009-03-12 2009-03-12
US61/159,534 2009-03-12

Publications (1)

Publication Number Publication Date
WO2010103469A1 true WO2010103469A1 (fr) 2010-09-16

Family

ID=42224766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/051031 WO2010103469A1 (fr) 2009-03-12 2010-03-10 Sonolyse de caillots sanguins utilisant des impulsions d'excitation codées de faible puissance

Country Status (1)

Country Link
WO (1) WO2010103469A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103845080A (zh) * 2014-02-25 2014-06-11 深圳京柏医疗设备有限公司 一种基于线性调频编码的超声脐带血流测量系统及方法
WO2014008405A3 (fr) * 2012-07-03 2014-07-17 Doheny Eye Institute Procédé de sonolyse
CN104363959A (zh) * 2012-05-11 2015-02-18 加利福尼亚大学董事会 在现场启动并监视中风患者治疗的便携式设备
WO2016092414A1 (fr) * 2014-12-11 2016-06-16 Koninklijke Philips N.V. Compensation d'épaisseur d'os temporal à base de signal de microbulles pour sonothrombolyse
WO2018138576A1 (fr) * 2017-01-25 2018-08-02 Insightec, Ltd. Localisation par cavitation
EP3412342A1 (fr) * 2017-06-09 2018-12-12 Theraclion Dispositifs de traitement thérapeutique et produit-programme d'ordinateur
CN112533541A (zh) * 2018-03-23 2021-03-19 阿德诺西特有限责任公司 诱导细胞和/或组织片段片状剥脱以增强细胞病理性细胞收集的方法
CN114947739A (zh) * 2022-04-18 2022-08-30 重庆邮电大学 双频微波诱导热声成像系统及方法
WO2022182648A1 (fr) * 2021-02-23 2022-09-01 Waveclear Inc. Procédé de commande d'un système d'intervention à ultrasons thérapeutique

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5181514A (en) 1991-05-21 1993-01-26 Hewlett-Packard Company Transducer positioning system
US5226422A (en) 1991-05-08 1993-07-13 Advanced Technology Laboratories, Inc. Transesophageal echocardiography scanner with rotating image plane
US5456257A (en) 1994-11-23 1995-10-10 Advanced Technology Laboratories, Inc. Ultrasonic detection of contrast agents
EP0770352A1 (fr) 1995-10-10 1997-05-02 Advanced Technology Laboratories, Inc. Imagerie diagnostique à ultrasons utilisant des agents de contraste
US5997479A (en) 1998-05-28 1999-12-07 Hewlett-Packard Company Phased array acoustic systems with intra-group processors
US6013032A (en) 1998-03-13 2000-01-11 Hewlett-Packard Company Beamforming methods and apparatus for three-dimensional ultrasound imaging using two-dimensional transducer array
US6050942A (en) 1997-07-11 2000-04-18 Atl Ultrasound Digital scanline signal processor for an ultrasonic diagnostic imaging system
US6283919B1 (en) 1996-11-26 2001-09-04 Atl Ultrasound Ultrasonic diagnostic imaging with blended tissue harmonic signals
US6340348B1 (en) 1999-07-02 2002-01-22 Acuson Corporation Contrast agent imaging with destruction pulses in diagnostic medical ultrasound
US6458083B1 (en) 1996-11-26 2002-10-01 Koninklijke Philips Electronics N.V. Ultrasonic harmonic imaging with adaptive image formation
US6530885B1 (en) 2000-03-17 2003-03-11 Atl Ultrasound, Inc. Spatially compounded three dimensional ultrasonic images
US6623432B2 (en) 2000-08-24 2003-09-23 Koninklijke Philips Electronics N.V. Ultrasonic diagnostic imaging transducer with hexagonal patches
US6716412B2 (en) 1997-09-15 2004-04-06 Imarx Therapeutics, Inc. Methods of ultrasound treatment using gas or gaseous precursor-filled compositions
US6723050B2 (en) 2001-12-19 2004-04-20 Koninklijke Philips Electronics N.V. Volume rendered three dimensional ultrasonic images with polar coordinates
WO2005074805A1 (fr) 2004-02-05 2005-08-18 Koninklijke Philips Electronics N.V. Imagerie ultrasonore d'irrigation et de debit sanguin au moyen d'agents de contraste harmoniques
EP1591073A1 (fr) * 2003-01-31 2005-11-02 Hitachi Medical Corporation Sonde ultrasonore et dispositif ultrasonore
WO2007018635A1 (fr) * 2005-08-05 2007-02-15 Siemens Medical Solutions Usa, Inc. Manipulation d'agents de contraste avec imagerie par ultrasons medicale
EP1790384A1 (fr) * 2005-11-23 2007-05-30 Siemens Medical Solutions USA, Inc. Système de thérapie par ultrasons avec un agent de contraste et guidance par imagerie à ultrason pour le traitement des thromboses
WO2008017997A2 (fr) 2006-08-11 2008-02-14 Koninklijke Philips Electronics, N.V. Système à ultrasons pour l'imagerie de la circulation sanguine cérébrale et la lyse de caillot sanguin au moyen de microbulles
WO2008039479A1 (fr) * 2006-09-27 2008-04-03 Siemens Medical Solutions Usa, Inc. thérapie automatisée par ultrasons améliorée par agents de contraste pour le traitement d'un thrombus
WO2008062342A2 (fr) * 2006-11-20 2008-05-29 Koninklijke Philips Electronics, N.V. Commande et affichage d'une cavitation de microbulles par ultrasons

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226422A (en) 1991-05-08 1993-07-13 Advanced Technology Laboratories, Inc. Transesophageal echocardiography scanner with rotating image plane
US5181514A (en) 1991-05-21 1993-01-26 Hewlett-Packard Company Transducer positioning system
US5456257A (en) 1994-11-23 1995-10-10 Advanced Technology Laboratories, Inc. Ultrasonic detection of contrast agents
EP0770352A1 (fr) 1995-10-10 1997-05-02 Advanced Technology Laboratories, Inc. Imagerie diagnostique à ultrasons utilisant des agents de contraste
US6283919B1 (en) 1996-11-26 2001-09-04 Atl Ultrasound Ultrasonic diagnostic imaging with blended tissue harmonic signals
US6458083B1 (en) 1996-11-26 2002-10-01 Koninklijke Philips Electronics N.V. Ultrasonic harmonic imaging with adaptive image formation
US6050942A (en) 1997-07-11 2000-04-18 Atl Ultrasound Digital scanline signal processor for an ultrasonic diagnostic imaging system
US6716412B2 (en) 1997-09-15 2004-04-06 Imarx Therapeutics, Inc. Methods of ultrasound treatment using gas or gaseous precursor-filled compositions
US6013032A (en) 1998-03-13 2000-01-11 Hewlett-Packard Company Beamforming methods and apparatus for three-dimensional ultrasound imaging using two-dimensional transducer array
US5997479A (en) 1998-05-28 1999-12-07 Hewlett-Packard Company Phased array acoustic systems with intra-group processors
US6340348B1 (en) 1999-07-02 2002-01-22 Acuson Corporation Contrast agent imaging with destruction pulses in diagnostic medical ultrasound
US6530885B1 (en) 2000-03-17 2003-03-11 Atl Ultrasound, Inc. Spatially compounded three dimensional ultrasonic images
US6623432B2 (en) 2000-08-24 2003-09-23 Koninklijke Philips Electronics N.V. Ultrasonic diagnostic imaging transducer with hexagonal patches
US6723050B2 (en) 2001-12-19 2004-04-20 Koninklijke Philips Electronics N.V. Volume rendered three dimensional ultrasonic images with polar coordinates
EP1591073A1 (fr) * 2003-01-31 2005-11-02 Hitachi Medical Corporation Sonde ultrasonore et dispositif ultrasonore
WO2005074805A1 (fr) 2004-02-05 2005-08-18 Koninklijke Philips Electronics N.V. Imagerie ultrasonore d'irrigation et de debit sanguin au moyen d'agents de contraste harmoniques
WO2007018635A1 (fr) * 2005-08-05 2007-02-15 Siemens Medical Solutions Usa, Inc. Manipulation d'agents de contraste avec imagerie par ultrasons medicale
EP1790384A1 (fr) * 2005-11-23 2007-05-30 Siemens Medical Solutions USA, Inc. Système de thérapie par ultrasons avec un agent de contraste et guidance par imagerie à ultrason pour le traitement des thromboses
WO2008017997A2 (fr) 2006-08-11 2008-02-14 Koninklijke Philips Electronics, N.V. Système à ultrasons pour l'imagerie de la circulation sanguine cérébrale et la lyse de caillot sanguin au moyen de microbulles
WO2008039479A1 (fr) * 2006-09-27 2008-04-03 Siemens Medical Solutions Usa, Inc. thérapie automatisée par ultrasons améliorée par agents de contraste pour le traitement d'un thrombus
WO2008062342A2 (fr) * 2006-11-20 2008-05-29 Koninklijke Philips Electronics, N.V. Commande et affichage d'une cavitation de microbulles par ultrasons

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. F. PROKOP ET AL.: "Mechanism Responsible for Ultrasound- accelerated Fibrinolysis in the Presence and Absence of OptisonTM", 2006 IEEE INTERNATIONAL ULTRASONICS SYMPOSIUM, October 2006 (2006-10-01)
S. DATTA ET AL.: "Correlation of Cavitation With Ultrasound Enhancement of Thrombolysis", ULT. IN MED. & BIOL., vol. 32, no. 8, 2006, pages 1257 - 1267

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104363959A (zh) * 2012-05-11 2015-02-18 加利福尼亚大学董事会 在现场启动并监视中风患者治疗的便携式设备
WO2014008405A3 (fr) * 2012-07-03 2014-07-17 Doheny Eye Institute Procédé de sonolyse
CN103845080A (zh) * 2014-02-25 2014-06-11 深圳京柏医疗设备有限公司 一种基于线性调频编码的超声脐带血流测量系统及方法
US10258313B2 (en) 2014-12-11 2019-04-16 Koninklijke Philips N.V. Microbubble signal based temporal-bone thickness compensation for sonothrombolysis
US20170360406A1 (en) * 2014-12-11 2017-12-21 Koninklijke Philips N.V. Microbubble signal based temporal-bone thickness compensation for sonothrombolysis
JP2017538492A (ja) * 2014-12-11 2017-12-28 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 超音波血栓溶解のためのマイクロバブル信号に基づく側頭骨厚補正
WO2016092414A1 (fr) * 2014-12-11 2016-06-16 Koninklijke Philips N.V. Compensation d'épaisseur d'os temporal à base de signal de microbulles pour sonothrombolyse
WO2018138576A1 (fr) * 2017-01-25 2018-08-02 Insightec, Ltd. Localisation par cavitation
CN110248606A (zh) * 2017-01-25 2019-09-17 医视特有限公司 气穴定位
US10575816B2 (en) 2017-01-25 2020-03-03 Insightec, Ltd. Cavitation localization
CN110248606B (zh) * 2017-01-25 2022-06-24 医视特有限公司 气穴定位
EP3412342A1 (fr) * 2017-06-09 2018-12-12 Theraclion Dispositifs de traitement thérapeutique et produit-programme d'ordinateur
US11253731B2 (en) 2017-06-09 2022-02-22 Theraclion Sa Devices for therapeutic treatment, method of operating a device for therapeutic treatment, and a computer program product
CN112533541A (zh) * 2018-03-23 2021-03-19 阿德诺西特有限责任公司 诱导细胞和/或组织片段片状剥脱以增强细胞病理性细胞收集的方法
WO2022182648A1 (fr) * 2021-02-23 2022-09-01 Waveclear Inc. Procédé de commande d'un système d'intervention à ultrasons thérapeutique
CN114947739A (zh) * 2022-04-18 2022-08-30 重庆邮电大学 双频微波诱导热声成像系统及方法

Similar Documents

Publication Publication Date Title
US20100056924A1 (en) Control and display of ultrasonic microbubble cavitation
WO2010103469A1 (fr) Sonolyse de caillots sanguins utilisant des impulsions d'excitation codées de faible puissance
JP5451819B2 (ja) 凝血塊を溶解するために組み合わされたイメージング及び治療トランスデューサを使用する方法
JP4667733B2 (ja) ステップ状チャープ波形を使用して超音波造影イメージングを増強する方法及び装置
US9198680B2 (en) Combination imaging and therapy transducer with therapy transducer amplifier
US6929609B2 (en) Ultrasonic diagnosing/treating device and method therefor
WO2012042423A1 (fr) Système de surveillance et de régulation de la cavitation de microbulles dans l'application thérapeutique d'ultrasons
EP1790384A1 (fr) Système de thérapie par ultrasons avec un agent de contraste et guidance par imagerie à ultrason pour le traitement des thromboses
CN107530555A (zh) 用于超声溶栓处置和监测的超声波换能器阵列
Li et al. A new active cavitation mapping technique for pulsed HIFU applications-bubble Doppler
US20080125657A1 (en) Automated contrast agent augmented ultrasound therapy for thrombus treatment
JP2009119299A (ja) 超音波の方法、および、該方法を実行するための回路
JP2002542869A (ja) 造影剤を用いた灌流の実時間超音波映像法
EP2076179B1 (fr) Séquences d'inversion d'impulsion pour imagerie non linéaire
US20080319316A1 (en) Combination Imaging and Therapy Transducer
US6783496B2 (en) Method and apparatus for improving contrast-to-tissue ratio in ultrasound contrast imaging with subharmonic imaging
US6514209B1 (en) Method of enhancing ultrasonic techniques via measurement of ultraharmonic signals
Shi et al. Spectral broadening in conventional and harmonic Doppler measurements with gaseous contrast agents
Haak et al. Detection of microbubble ultrasound contrast agent destruction applied to Definity
US20190069875A1 (en) Ultrasound system for cerebral blood flow imaging and microbubble-enhanced blood clot lysis
JP7170359B1 (ja) 超音波画像処理装置
Hägglund Development of a Tool for Imaging the Pumping-Out Behavior of Poly-Vinyl Alcohol Shelled Microbubbles
KOYAMA et al. Improved Monitoring of Intracranial Echo-guided Surgery: Reduction of Backscattering and Recognition of the Operating Part Using Microcapsule Vibration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10714479

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10714479

Country of ref document: EP

Kind code of ref document: A1